Diversified health care giant Johnson & Johnson (NYSE:JNJ) saw continued fallout from a flurry of product recalls and concerns over its manufacturing controls as investors sent the stock towards its lows over the past year. The company also didn't bother to provide a full balance sheet or cash flow statement during its fourth quarter results, leaving investors to wonder about its finances and cash flows until it files full-year financial statements with the Securities and Exchange Commission.

IN PICTURES: 6 Simple Steps To $1 Million

Fourth Quarter Recap
The earnings press release did provide an income statement that detailed a 5.5% sales decline to $15.6 billion. Of the three operating divisions, the consumer unit was the notable laggard as sales fell 15% to account for 23% of sales. Product recalls of over-the-counter medicines hit the unit, as did a hip device recall in the DePuy medical device franchise, though total medical device sales eeked out 0.1% growth to account for just over 40% of total sales. The pharma unit saw sales decline a modest 4.7% to account for the remainder of the top line, as U.S. sales fell 5.7% and international decreased 1.6%.

Geographically, sales were strongest in Asia, rising 9.7% to account for 19.2% of sales. Sales fell 8.1% in the U.S. (46.2% of total sales), 10.5% in Europe (25.6%) and 4.5% everywhere else in the Western Hemisphere (9%). Product costs fell only 5.1% but management was able to reduce selling, general and administrative costs by 8%. However, $1.1 billion in recall and related expenses sent operating income down 14.4% to $2.2 billion. Net income fell 12% to $1.9 billion, or 70 cents per diluted share.

Year End Review and Outlook
Full-year sales fell 0.5% to $61.6 billion. The lack of a restructuring charge compared to last year helped push operating income ahead to $17 billion while net income rose 8.7% to $13.3 billion, or $4.78 per diluted share.

For the coming year, management said to expect earnings between $4.80 and $4.90 per share, though there again could be a number of "special items." At best, this would represent year-over-year growth of a couple of percent. Analysts project a similar level of full-year sales growth.

Bottom Line
At the current earnings valuation, shares of J&J are cheap at 12.4 times forward expectations. This represents one of the lowest multiples in the last 20 years, but it is warranted given the quality concerns and hits to the company's once solid image. Fortunately, none of the current issues appear to be serious and the company is still growing modestly. Overall though, a number of rivals, including Medtronic (NYSE:MDT), Teva Pharmaceutical (Nasdaq:TEVA), Roche (OTC:RHHBY), and Novartis (NYSE:NVS) trade at equally appealing valuations and have their acts together in terms of product manufacturing.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  2. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  3. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  4. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  5. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  6. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  7. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!